The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | RWD from INSIGHT-MM: duration of therapy and treatment sequencing
Guy Pratt, MD, FRCP, FRCPath, of University of Birmingham, Birmingham, UK, highlights data coming from a UK-specific analysis of the INSIGHT MM study (NCT02761187). This analysis showed a clear variability in treatment selection and sequencing and treatment discontinuation in UK practice for patients with multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
